DAIC Articles

Boston Scientific Corp. has commenced enrollment in the HI-PEITHO clinical trial, a collaborative research study with the Pulmonary Embolism Response Team (PERT) Consortium and the University Medical Center of the Johannes Gutenberg University of Mainz comparing use of the EkoSonic Endovascular System in combination with anticoagulation to anticoagulation alone for the treatment of acute, intermediate-high-risk […]

The U.S. Food and Drug Administration (FDA) has cleared the Angel Medical Systems Inc. second-generation AngelMed Guardian device. It is the world’s first implantable cardiac detection monitor and patient-warning system for acute coronary syndrome (ACS) events, including silent heart attacks. The new, second-generation device is enhanced with ease-of-use adaptations and an updated, long life battery […]

The HLT Meridian TAVR Valve System is designed to overcome some of the challenges of current FDA-cleared TAVR devices.

This “hyperinvasive” approach performed better than expected outcomes also seen in patients who received standard advanced cardiac life support.

The Consumer Technology Association (CTA) is collaborating with the American College of Cardiology (ACC) and several vendors on best practices for device and app and wearable device makers to provide deeper understanding of products that manage cardiovascular health.

Today, as TAVR now makes up more procedural volume in the U.S. than surgical aortic replacements, many hospitals that have not already created a structural heart program are now looking at creating one.

National Heart, Lung, and Blood Institute (NHLBI) has awarded a grant of $462,689 to Rhythm Therapeutics Inc. (RTI) to complete the phase 1 segment of the development of a novel gene therapy to treat atrial fibrillation (AF). It involves using electroporation to create temporary openings in cardiac cells to deliver therapeutic transgenes targeting the underlying […]

Elixir Medical recently announced the first patient was treated in the BIOADAPTOR randomized controlled trial (RCT) of the DynamX Coronary Bioadaptor System, the first drug-eluting coronary stent that adapts to vessel physiology.

Class I recall includes Evera, Viva, Brava, Claria, Amplia, Compia and Visia implantable cardioverter defibrillators and cardiac resynchronization therapy devices.

In the early 2000s, the cardiology department at WHS Washington Hospital needed to replace an outdated paper reporting system with a modern system that could streamline workflows, reduce redundant data entry, and balance workloads.